Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 144

1.

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.

Nakai Y, Tanaka N, Asakawa I, Torimoto K, Miyake M, Anai S, Fujii T, Hasegawa M, Fujimoto K.

J Contemp Brachytherapy. 2019 Oct;11(5):409-416. doi: 10.5114/jcb.2019.88142. Epub 2019 Oct 30.

2.

Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.

Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Yamaki K, Hasegawa M, Fujimoto K.

Jpn J Clin Oncol. 2019 Oct 28. pii: hyz136. doi: 10.1093/jjco/hyz136. [Epub ahead of print]

PMID:
31665354
3.

Factors contributing to the ceiling effect of the EQ-5D-5L: an analysis of patients with prostate cancer judged "no-problems".

Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Wakumoto Y, Tanaka N, Sugimoto M, Oyama M, Fujimoto K, Horie S, Funagoshi M, Arakawa I, Noto S, Shimozuma K.

Qual Life Res. 2019 Oct 3. doi: 10.1007/s11136-019-02316-4. [Epub ahead of print]

PMID:
31583618
4.

Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan.

Tanaka N, Asakawa I, Hasegawa M, Fujimoto K.

Int J Urol. 2019 Sep 24. doi: 10.1111/iju.14098. [Epub ahead of print] Review.

PMID:
31549770
5.

A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'.

Miyake M, Maesaka F, Marugami N, Miyamoto T, Nakai Y, Ohnishi S, Gotoh D, Owari T, Hori S, Morizawa Y, Itami Y, Inoue T, Anai S, Torimoto K, Fujii T, Shimada K, Tanaka N, Fujimoto K.

Diagnostics (Basel). 2019 Sep 4;9(3). pii: E112. doi: 10.3390/diagnostics9030112.

6.

Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder.

Shiota T, Torimoto K, Okuda M, Iwata R, Kumamoto H, Miyake M, Hirayama A, Tanaka N, Fujimoto K.

Low Urin Tract Symptoms. 2019 Aug 28. doi: 10.1111/luts.12285. [Epub ahead of print]

PMID:
31460706
7.

Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis.

Morizawa Y, Aoki K, Iemura Y, Hori S, Gotoh D, Fukui S, Nakai Y, Miyake M, Torimoto K, Tanaka N, Fujimoto K.

Neurourol Urodyn. 2019 Nov;38(8):2311-2317. doi: 10.1002/nau.24142. Epub 2019 Aug 20.

PMID:
31432572
8.

Evaluation of Preoperative Abdominal Adipose Tissue-, Inflammation-, Muscle Mass-, and Nutritional Status-based Prognostic Markers to Assess Renal Dysfunction in Living Kidney Donors.

Hori S, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Miyake M, Anai S, Torimoto K, Aoki K, Yoneda T, Tanaka N, Yoshida K, Fujimoto K.

Transplant Proc. 2019 Jul - Aug;51(6):1706-1716. doi: 10.1016/j.transproceed.2019.04.057.

PMID:
31399161
9.

Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.

Miyake M, Hori S, Ohnishi S, Toritsuka M, Fujii T, Shimizu T, Owari T, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K.

Cancer Sci. 2019 Oct;110(10):3315-3327. doi: 10.1111/cas.14158. Epub 2019 Aug 19.

10.

The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.

Miyake M, Tanaka N, Asakawa I, Owari T, Hori S, Morizawa Y, Nakai Y, Inoue T, Anai S, Torimoto K, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5.

11.

Clinical Significance of Postoperative Nutritional Status as a Prognostic Factor in Kidney Transplant Recipients.

Hori S, Ichikawa K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Miyake M, Yoneda T, Tanaka N, Yoshida K, Fujimoto K.

Transplant Proc. 2019 Jul - Aug;51(6):1763-1772. doi: 10.1016/j.transproceed.2019.04.047. Epub 2019 Jun 27.

PMID:
31255359
12.

Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.

Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K.

Diseases. 2019 Jun 18;7(2). pii: E44. doi: 10.3390/diseases7020044.

13.

Tadalafil, a phosphodiesterase type 5 inhibitor, restores urethra and detrusor function in the initial phase of diabetes in rats.

Gotoh D, Torimoto K, Iwasaki H, Iwamoto T, Morizawa Y, Hori S, Miyake M, Tanaka N, Hirayama A, Nishi E, Fujimoto K.

Low Urin Tract Symptoms. 2019 Sep;11(4):241-247. doi: 10.1111/luts.12272. Epub 2019 Jun 17.

PMID:
31207119
14.

Evaluation of pro‑ and anti‑tumor effects induced by three colony‑stimulating factors, G‑CSF, GM‑CSF and M‑CSF, in bladder cancer cells: Is G‑CSF a friend of bladder cancer cells?

Hori S, Miyake M, Onishi S, Morizawa Y, Nakai Y, Tatsumi Y, Onishi K, Iida K, Gotoh D, Itami Y, Tanaka N, Fujimoto K.

Int J Oncol. 2019 Jun;54(6):2237-2249. doi: 10.3892/ijo.2019.4772. Epub 2019 Apr 4.

PMID:
31081057
15.

Genitourinary toxicity after permanent iodine-125 seed implantation: The nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS).

Tanaka N, Yorozu A, Kikuchi T, Higashide S, Kojima S, Ohashi T, Katayama N, Nakamura K, Saito S, Dokiya T, Fukushima M; J-POPS Study Group.

Brachytherapy. 2019 Jul - Aug;18(4):484-492. doi: 10.1016/j.brachy.2019.03.007. Epub 2019 May 6.

PMID:
31072729
16.

Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.

Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y.

Int J Urol. 2019 Aug;26(8):797-803. doi: 10.1111/iju.14009. Epub 2019 May 5.

PMID:
31055879
17.

Health utility and health-related quality of life of Japanese prostate cancer patients according to progression status measured using EQ-5D-5L and FACT-P.

Murasawa H, Sugiyama T, Matsuoka Y, Okabe T, Hino A, Tanaka N, Sugimoto M, Oyama M, Fujimoto K, Horie S, Noto S, Shimozuma K.

Qual Life Res. 2019 Sep;28(9):2383-2391. doi: 10.1007/s11136-019-02184-y. Epub 2019 Apr 25.

PMID:
31025290
18.

Long-term Changes in Renal Function, Blood Electrolyte Levels, and Nutritional Indices after Radical Cystectomy and Ileal Conduit in Patients with Bladder Cancer.

Miyake M, Owari T, Tomizawa M, Matsui M, Nishibayashi N, Iida K, Onishi K, Hori S, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Tanaka N, Fujimoto K.

Urol J. 2019 May 5;16(2):145-151. doi: 10.22037/uj.v0i0.4531.

19.

Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume.

Hori S, Tanaka N, Nakai Y, Morizawa Y, Tatsumi Y, Miyake M, Anai S, Fujii T, Konishi N, Nakagawa Y, Hirao S, Fujimoto K.

Res Rep Urol. 2019 Mar 19;11:61-68. doi: 10.2147/RRU.S193933. eCollection 2019.

20.

Prognostic impact of tumor-infiltrating CD276/Foxp3-positive lymphocytes and associated circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma.

Iida K, Miyake M, Onishi K, Hori S, Morizawa Y, Gotoh D, Itami Y, Onishi S, Nakai Y, Anai S, Tanaka N, Fujimoto K.

Oncol Lett. 2019 Apr;17(4):4004-4010. doi: 10.3892/ol.2019.10057. Epub 2019 Feb 20.

Supplemental Content

Loading ...
Support Center